ASCO 2024 Updates: nccRCC + Chromophobe RCC
Key opinion leaders analyze the latest advancements and research findings specific to Non-Clear Cell Renal Cell Carcinoma presented at the American Society of Clinical Oncology 2024 conference.
CN24_BTL_RCC_Seg04_Chromophobe
Video Player is loading.
EP: 1.Overview of RCC Histology and Incidence Rates
EP: 2.CLEAR Trial Updates From ASCO 2024
EP: 3.TKIs, Disease Progression and Subsequent Therapy in RCC
Now Viewing
EP: 4.ASCO 2024 Updates: nccRCC + Chromophobe RCC
EP: 5.PAPMET Phase II Trial Advances Cancer Treatment Landscape
EP: 6.Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis
EP: 7.Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence
EP: 8.ASCO 2024: Abstract 4512 Overview
EP: 9.Key Takeaways in Renal Cell Carcinoma from Abstract 4512
EP: 10.Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
Related Content
